Avego Bioscience Capital

Avego Bioscience Capital is a venture capital firm specializing in investments within the biotechnology sector across the United States. The firm focuses on early to late-stage companies, including Series A, Series B, growth, late-stage, and pre-IPO stages. Avego's investment strategy encompasses a broad spectrum of biotechnology and healthcare companies, aiming to support innovative solutions in the healthcare continuum. The firm has been actively involved in financing rounds for companies such as TRex Bio, Inc., which secured an $84 million Series B financing led by Avego in November 2024. Additionally, Avego has invested in Evommune, Inc., a clinical-stage biotechnology company developing therapies for immune-mediated chronic inflammatory diseases, and Aro Biotherapeutics, Inc., focusing on tissue-targeted genetic medicines. These investments reflect Avego's commitment to advancing healthcare through strategic partnerships with innovative biotech firms.

Avego's portfolio also includes AtomVie Global Radiopharma Inc., a contract development and manufacturing organization for radiotherapeutics, and Sebela Pharmaceuticals, a commercial-stage specialty pharmaceutical company. The firm's diverse portfolio underscores its dedication to supporting a wide range of healthcare solutions, from radiopharmaceuticals to specialty pharmaceuticals. Avego's approach combines financial expertise with a deep understanding of the healthcare sector, enabling it to identify and nurture companies with high growth potential.

Through its strategic investments, Avego Bioscience Capital plays a pivotal role in advancing healthcare innovation, supporting companies that are at the forefront of developing transformative therapies and medical solutions. The firm's active participation in significant financing rounds and its diverse portfolio highlight its influential presence in the biotechnology investment landscape.